{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:35:55Z","timestamp":1783654555674,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2002,7]]},"DOI":"10.1053\/ajkd.2002.34681","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T23:46:10Z","timestamp":1030232770000},"page":"202-204","source":"Crossref","is-referenced-by-count":27,"title":["Lead, renal disease and hypertension"],"prefix":"10.1053","volume":"40","author":[{"given":"Harvey C.","family":"Gonick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/ajkd.2002.34681_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1053\/ajkd.2002.33912","article-title":"Erythrocyte aminolevulinate dehydratase activity as a lead marker in patients with chronic renal failure","volume":"40","author":"Fontanellas","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.34681_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/ajkd.2002.33936","article-title":"Experimental lead nephropathy: Treatment with calcium disodium ethylenediaminetetraacetate","volume":"40","author":"S\u00e1nchez-Fructuoso","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.34681_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/ajkd.2002.33913","article-title":"Lead mobilization during calcium disodium ethylenediaminetetraacetate chelation therapy in the treatment of chronic lead poisoning","volume":"40","author":"S\u00e1nchez-Fructuoso","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.34681_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archinte.1979.03630380035014","article-title":"Detection and treatment of occupational lead nephropathy","volume":"139","author":"Wedeen","year":"1979","journal-title":"Arch Intern Med"},{"key":"10.1053\/ajkd.2002.34681_bib5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM198102263040905","article-title":"The role of lead in gout nephropathy","volume":"304","author":"Batuman","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1053\/ajkd.2002.34681_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM198307073090104","article-title":"Contribution of lead to hypertension with renal impairment","volume":"309","author":"Batuman","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1053\/ajkd.2002.34681_bib7","first-page":"310","article-title":"Chronic lead nephropathy: The diagnostic use of calcium EDTA and the association with gout","volume":"12","author":"Emmerson","year":"1963","journal-title":"Aust NZ J Med"},{"key":"10.1053\/ajkd.2002.34681_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ki.1988.39","article-title":"Bone lead in dialysis patients","volume":"33","author":"Van de Vyver","year":"1988","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2002.34681_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/00039896.1995.9935967","article-title":"Clinical application of in vivo tibial K-XRF for monitoring lead stores","volume":"50","author":"Wedeen","year":"1995","journal-title":"Arch Environ Health"},{"key":"10.1053\/ajkd.2002.34681_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00378090","article-title":"Increase in the amount of erythrocyte delta-aminolevulinic acid dehydratase in workers with moderate lead exposure","volume":"50","author":"Fujita","year":"1982","journal-title":"Int Arch Occup Environ Health"},{"key":"10.1053\/ajkd.2002.34681_bib11","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/01.HYP.30.6.1487","article-title":"Lead-induced hypertension: Interplay of nitric oxide and reactive oxygen species","volume":"30","author":"Gonick","year":"1997","journal-title":"Hypertension"},{"key":"10.1053\/ajkd.2002.34681_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1006\/enrs.1997.3796","article-title":"Lead-induced hypertension. II. Response to sequential infusions of L-arginine, superoxide dismutase, and nitroprusside","volume":"76","author":"Ding","year":"1998","journal-title":"Environ Res"},{"key":"10.1053\/ajkd.2002.34681_bib13","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/ki.1997.426","article-title":"Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: Effect of lazaroid therapy","volume":"52","author":"Vaziri","year":"1997","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2002.34681_bib14","first-page":"804","article-title":"Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy","volume":"243","author":"Cory-Slechta","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/ajkd.2002.34681_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/BF03259865","article-title":"Chronic low-level lead exposure. Its role in the pathogenesis of hypertension","volume":"2","author":"Sharp","year":"1987","journal-title":"Med Toxicol"},{"key":"10.1053\/ajkd.2002.34681_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/enrs.1994.1023","article-title":"Effect of chelation treatment with dimercaptosuccinic acid (DMSA) on lead-related blood pressure changes","volume":"65","author":"Khalil-Manesh","year":"1994","journal-title":"Environ Res"},{"key":"10.1053\/ajkd.2002.34681_bib17","first-page":"679","article-title":"Compensatory up-regulation of nitric-oxide synthase isoforms in lead-induced hypertension; reversal by a superoxide dismutase-mimetic drug","volume":"298","author":"Vaziri","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/ajkd.2002.34681_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0013-9351(89)80086-6","article-title":"Reducing bone lead content by chelation treatment in chronic lead poisoning: An in vivo X-ray fluorescence and bone biopsy study","volume":"48","author":"Batuman","year":"1989","journal-title":"Environ Res"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638602000264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638602000264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T16:20:45Z","timestamp":1554913245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638602000264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["S0272638602000264"],"URL":"https:\/\/doi.org\/10.1053\/ajkd.2002.34681","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}